{"content":"<li class=\"n-box-item date-title\" data-end=\"1504238399\" data-start=\"1504152000\" data-txt=\"Monday, December 23, 2019\">Thursday, August 31, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3293101\" data-ts=\"1504222391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVHY\" target=\"_blank\">VIVHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293101-vivendiplus-3_3-after-music-powered-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivendi +3.3% after music-powered revenue beat</a></h4><ul>   <li>Vivendi (<a href='https://seekingalpha.com/symbol/VIVHY' title='Vivendi SA ADR'>OTCPK:VIVHY</a>) finished <font color='green'>up 3.3%</font> after posting <a href=\"https://seekingalpha.com/news/3292991-vivendi-sa-reports-q2-results\" target=\"_blank\">Q2 results</a> where its revenues beat expectations with the help of improvements at Universal Music (powered by summer hit <i>Despacito)</i> and its struggling Canal Plus TV unit.</li>    <li>EBITA of &euro;203M was up 16% Y/Y; EBITA at Universal Music Group rose 52.5%, to &euro;152M, while Canal Plus fell 5.5% to &euro;114M.</li>    <li>Revenues grew nearly 8% for the first half, to &euro;5.437B, with 14% growth at UMG. Canal Plus revenues, meanwhile, fell 2.4% Y/Y for the half, but the company pointed to a slowing decline.</li>    <li>First-half net income was up 12% to &euro;320M.</li>    <li>It's reaffirmed full-year guidance for revenues growing more than 5% (excluding Havas) and EBITA rising by about 25%. That includes confirming Canal Plus EBITA hitting &euro;350M vs. a year-ago &euro;240M.</li>    <li><a href=\"https://www.vivendi.com/wp-content/uploads/2017/08/20170831_VIV_PR_Vivendi-half-year-2017-results.pdf\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3293101\" data-linked=\"Vivendi +3.3% after music-powered revenue beat\" data-tweet=\"$VIVHY - Vivendi +3.3% after music-powered revenue beat https://seekingalpha.com/news/3293101-vivendiplus-3_3-after-music-powered-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3293101-vivendiplus-3_3-after-music-powered-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293100\" data-ts=\"1504220838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APVO\" target=\"_blank\">APVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293100-aptevo-therapeutics-to-develop-drug-candidate-on-own-sharesplus-110\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptevo Therapeutics to develop drug candidate on its own; shares +110%</a></h4><ul>     <li>Aptevo&nbsp;Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) <font color='green'>+110.5%</font> AH after saying it <a href=\"https://seekingalpha.com/pr/16929239-aptevo-therapeutics-morphosys-end-joint-development-commercialization-agreement-mor209-es414\" target=\"_blank\">ended its partnership</a> with MorphoSys for the joint development and commercialization of the APVO414 prostate cancer drug, and will develop the drug on its own.</li>     <li>APVO says it plans to continue to advance the drug through the completion of Stage 1 of an ongoing Phase 1 clinical study of the treatment of metastatic castration resistant prostate cancer.</li>     <li>Separately, APVO <a href=\"https://seekingalpha.com/pr/16929242-aptevo-therapeutics-signs-agreement-74_5-million-sell-hyperimmune-commercial-products\" target=\"_blank\">agrees to sell</a> three of its marketed hyperimmune products to Saol Therapeutics for $65M plus as much as $9.5M in milestone payments and accounts receivable payments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293100\" data-linked=\"Aptevo Therapeutics to develop drug candidate on its own; shares +110%\" data-tweet=\"$APVO - Aptevo Therapeutics to develop drug candidate on its own; shares +110% https://seekingalpha.com/news/3293100-aptevo-therapeutics-to-develop-drug-candidate-on-own-sharesplus-110?source=tweet\" data-url=\"https://seekingalpha.com/news/3293100-aptevo-therapeutics-to-develop-drug-candidate-on-own-sharesplus-110\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293097\" data-ts=\"1504218357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IOVA\" target=\"_blank\">IOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293097-iovance-biotherapeuticsplus-13-on-fda-fast-track-designation-for-lnminus-144\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iovance Biotherapeutics +13% on FDA fast track designation for LN-144</a></h4><ul>     <li>Iovance Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a>) <font color='green'>+13.1%</font> AH after saying the FDA had <a href=\"https://seekingalpha.com/pr/16929206-iovance-biotherapeutics-announces-fda-fast-track-designation-lnminus-144-treatment-advanced\" target=\"_blank\">granted fast track designation</a> for LN-144, the company's lead product.</li>     <li>LN-144 is an adoptive cell therapy using tumor-infiltrating lymphocyte technology being investigated for the treatment of patients with metastatic melanoma.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293097\" data-linked=\"Iovance Biotherapeutics +13% on FDA fast track designation for LN-144\" data-tweet=\"$IOVA - Iovance Biotherapeutics +13% on FDA fast track designation for LN-144 https://seekingalpha.com/news/3293097-iovance-biotherapeuticsplus-13-on-fda-fast-track-designation-for-lnminus-144?source=tweet\" data-url=\"https://seekingalpha.com/news/3293097-iovance-biotherapeuticsplus-13-on-fda-fast-track-designation-for-lnminus-144\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293089\" data-ts=\"1504213498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEO\" target=\"_blank\">TEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293089-cablevision-shareholders-approve-telecom-argentina-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cablevisión shareholders approve Telecom Argentina merger</a></h4><ul>   <li>In a filing, Argentina's Cablevisi&oacute;n says shareholders have approved its merger with Telecom Argentina (<a href=\"http://seekingalpha.com/symbol/TEO\" target=\"_blank\">TEO</a> <font color='red'>-3.8%</font>).</li>    <li>The measure was unanimously approved, according to Bloomberg. The two <a href=\"https://seekingalpha.com/news/3276649-telecom-argentina-cablevision-merge-broadband-leader\" target=\"_blank\">announced the deal July 1</a>.</li>    <li>The combination of two leading Internet service providers will allow the two to get into quadruple-play bundling when the country opens its market to such offerings, and to present a more unified broadband competitor to Claro (<a href=\"http://seekingalpha.com/symbol/AMX\" target=\"_blank\">AMX</a> <font color='red'>-0.7%</font>) and to the local unit of Telefonica (<a href=\"http://seekingalpha.com/symbol/TEF\" target=\"_blank\">TEF</a> <font color='green'>+0.4%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293089\" data-linked=\"Cablevisión shareholders approve Telecom Argentina merger\" data-tweet=\"$TEO $TEO $AMX - Cablevisión shareholders approve Telecom Argentina merger https://seekingalpha.com/news/3293089-cablevision-shareholders-approve-telecom-argentina-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3293089-cablevision-shareholders-approve-telecom-argentina-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293086\" data-ts=\"1504213297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293086-palo-alto-networks-gains-6_4-after-q4-guidance-beats-and-record-billings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks gains 6.4% after Q4, guidance beats and record billings</a></h4><ul><li>        Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>) shares are&nbsp;<font color='green'>up 6.4%&nbsp;</font>aftermarket following Q4 EPS and revenue beats. Q3 outlook puts revenue from $482M to $492M, compared to $489.76M consensus, and has EPS straddling estimates at $0.67 to $0.69. FY18 guidance has revenue from $2.125B to $2.165B, mostly beating the $2.13B estimate, and EPS from $3.24 to $3.34 with $3.27 consensus. &nbsp;</li><li>        Product revenue totaled $212.3M, up 11%, with the number expected to fall in Q1 to $170M to $173M but total $735M to $750M for FY18. Subscription and support revenue was $296.8M, up 42% on the year.</li><li>               Total billings were up 17% to $670.8M and expected to fall between $580M and $600M in Q1 and $2.64B to $2.7B for FY18. Deferred revenue was up 43% to $1.8B.&nbsp;</li><li>               Other key metrics: Operating expenses totaled $397.9M. Cash flow from operations were $240M and FCF $190M. The company ended the quarter with $2.2B in cash and equivalents.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16929117-palo-alto-networks-reports-fiscal-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293059-palo-alto-networks-beats-0_13-beats-revenue\" target=\"_blank\">Palo Alto Networks beats by $0.13, beats on revenue</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293086\" data-linked=\"Palo Alto Networks gains 6.4% after Q4, guidance beats and record billings\" data-tweet=\"$PANW - Palo Alto Networks gains 6.4% after Q4, guidance beats and record billings https://seekingalpha.com/news/3293086-palo-alto-networks-gains-6_4-after-q4-guidance-beats-and-record-billings?source=tweet\" data-url=\"https://seekingalpha.com/news/3293086-palo-alto-networks-gains-6_4-after-q4-guidance-beats-and-record-billings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293075\" data-ts=\"1504211401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293075-ambarella-shares-up-2_9-after-q2-guidance-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambarella shares up 2.9% after Q2, guidance beats</a></h4><ul><li>        Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a>) shares are&nbsp;<font color='green'>up 2.9%</font>&nbsp;aftermarket following a Q2 report that beat EPS and revenue estimates. The Q3 revenue outlook straddles consensus with a guided $87.5M to $90.5M compared to the $88.9M Street estimate. &nbsp;</li><li>        Non-GAAP gross margin was 63%, down from 67.1% from the prior year&rsquo;s quarter. The number should come in-line to lower in Q3 with a predicted range of 62% to 63.5%. &nbsp;Operating expenses totaled $39.5M (+15% Y/Y) with $27.5M (+16%) from R&amp;D and $12M from SG&amp;A (+13%). Q3 operating expenses expected between $28M and $29.5M. The company ended the quarter with $400.8M in cash and equivalents</li><li>        <a href=\"https://seekingalpha.com/pr/16929101-ambarella-inc-announces-second-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3293052-ambarella-beats-0_04-beats-revenue\" target=\"_blank\">Ambarella beats by $0.04, beats on revenue</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293075\" data-linked=\"Ambarella shares up 2.9% after Q2, guidance beats\" data-tweet=\"$AMBA - Ambarella shares up 2.9% after Q2, guidance beats https://seekingalpha.com/news/3293075-ambarella-shares-up-2_9-after-q2-guidance-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3293075-ambarella-shares-up-2_9-after-q2-guidance-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293069\" data-ts=\"1504210757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293069-lululemon-rallies-after-lifting-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon rallies after lifting guidance</a></h4><ul>     <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) reports comparable sales increased 7% in <a href=\"https://seekingalpha.com/pr/16850510-lululemon-athletica-inc-announces-first-quarter-fiscal-2017-results-plan-restructure-ivivva\" target=\"_blank\">Q2</a>. On a constant dollar basis, comparable sales were up 2%.</li>     <li>Gross margin was 51.6% of sales during the quarter vs. 50.5% expected and 49.4% a year ago.</li>     <li>Operating margin fell 160 bps to 12.8% of sales during the quarter.</li>     <li>\"The acceleration that we have seen across the business in the second quarter enables us to take another positive step on our path towards achieving $4 billion in revenue by 2020,\" says Lululemon CEO Laurent Potdevin.</li>     <li>Looking ahead, Lululemon sees full-year revenue of $2.55B to $2.60B vs. $2.55B consensus and full-year EPS $2.35 to $2.42 vs. $2.32 consensus.</li>      <li>LULU <font color='green'>+7.75%</font> premarket to $61.99.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293069\" data-linked=\"Lululemon rallies after lifting guidance\" data-tweet=\"$LULU - Lululemon rallies after lifting guidance https://seekingalpha.com/news/3293069-lululemon-rallies-after-lifting-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3293069-lululemon-rallies-after-lifting-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293059\" data-ts=\"1504210305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293059-palo-alto-networks-beats-0_13-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks beats by $0.13, beats on revenue</a></h4><ul><li>Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>): Q4 EPS of $0.92 <font color='green'>beats by $0.13</font>.</li><li>Revenue of $509.1M (+27.0% Y/Y) <font color='green'>beats by $21.76M</font>.</li><li>Shares <font color='green'>+2.49%</font>.</li><li><a href='https://seekingalpha.com/pr/16929117-palo-alto-networks-reports-fiscal-fourth-quarter-fiscal-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293059\" data-linked=\"Palo Alto Networks beats by $0.13, beats on revenue\" data-tweet=\"$PANW - Palo Alto Networks beats by $0.13, beats on revenue https://seekingalpha.com/news/3293059-palo-alto-networks-beats-0_13-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293059-palo-alto-networks-beats-0_13-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293054\" data-ts=\"1504210037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293054-piper-jaffray-lowers-ciena-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray lowers Ciena price target</a></h4><ul><li>        Piper Jaffray reduces the price target for Ciena (NASDAQ:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) from $32 to $30 but reiterates its Overweight rating.</li><li>               Analyst Troy Jensen cites the strong quarterly results and sees the company as the supplier best positioned for Metro and DCI.&nbsp;</li><li>               Jensen believes Ciena will lead revenue growth in the industry for several years.&nbsp;</li><li>               Source: <a href=\"https://thefly.com/landingPageNews.php?id=2603518&amp;headline=CIEN-Piper-says-Ciena-best-positioned-supplier-in-two-hottest-optical-segments\" target=\"_blank\">The Fly</a>&nbsp;</li><li>               Ciena shares closed today&nbsp;<font color='red'>down 11.04%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292887-ciena-beats-q2-estimates-issues-weak-guidance-shares-8_6-percent\" target=\"_blank\">Ciena beats Q2 estimates, issues weak guidance; shares down 8.6%</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293054\" data-linked=\"Piper Jaffray lowers Ciena price target\" data-tweet=\"$CIEN - Piper Jaffray lowers Ciena price target https://seekingalpha.com/news/3293054-piper-jaffray-lowers-ciena-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3293054-piper-jaffray-lowers-ciena-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293051\" data-ts=\"1504209951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293051-lululemon-athletica-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon Athletica beats by $0.04, beats on revenue</a></h4><ul><li>Lululemon Athletica (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>): Q2 EPS of $0.39 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $581.05M (+12.9% Y/Y) <font color='green'>beats by $13.45M</font>.</li><li>Shares <font color='green'>+4.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16929081-lululemon-athletica-inc-announces-second-quarter-fiscal-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293051\" data-linked=\"Lululemon Athletica beats by $0.04, beats on revenue\" data-tweet=\"$LULU - Lululemon Athletica beats by $0.04, beats on revenue https://seekingalpha.com/news/3293051-lululemon-athletica-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293051-lululemon-athletica-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293050\" data-ts=\"1504209868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293050-nutanix-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix beats by $0.05, beats on revenue</a></h4><ul><li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>): Q4 EPS of -$0.33 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $226.1M (+61.7% Y/Y) <font color='green'>beats by $8.05M</font>.</li><li>Shares <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/pr/16929076-nutanix-reports-fourth-quarter-fiscal-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293050\" data-linked=\"Nutanix beats by $0.05, beats on revenue\" data-tweet=\"$NTNX - Nutanix beats by $0.05, beats on revenue https://seekingalpha.com/news/3293050-nutanix-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293050-nutanix-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293042\" data-ts=\"1504207928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293042-arizona-ag-sues-insys-over-fraudulent-opioid-marketing-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arizona AG sues Insys over &quot;fraudulent&quot; opioid marketing; shares down 4%</a></h4><ul><li>Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='red'>-4.3%</font>) slips on modestly higher volume in response to the <a href=\"http://www.reuters.com/article/us-insys-court-idUSKCN1BB23U?utm_campaign=trueAnthem:+Trending+Content&amp;utm_content=59a8616304d301079f824768&amp;utm_medium=trueAnthem&amp;utm_source=twitter\" target=\"_blank\">news </a>that Arizona's attorney general has filed a lawsuit against the company accusing it of \"fraudulent\" marketing aimed at boosting sales of Subsys (fentanyl), an opioid pain medication.</li><li>The lawsuit asserts that the company paid doctors sham speaker fees in exchange for writing prescriptions for Subsys without regard for the health of the patients. It also names three Arizona physicians who collected speaker fees from the company while writing prescriptions that generated more than $33M in sales of the product.</li><li>The company did not immediately respond to a request for comment. It recently agreed to pay almost $9M to settle litigation in Oregon, New Hampshire and Illinois.</li><li>Source: Reuters</li></ul><div class=\"tiny-share-widget\" data-id=\"3293042\" data-linked=\"Arizona AG sues Insys over &quot;fraudulent&quot; opioid marketing; shares down 4%\" data-tweet=\"$INSY $INSYQ - Arizona AG sues Insys over &quot;fraudulent&quot; opioid marketing; shares down 4% https://seekingalpha.com/news/3293042-arizona-ag-sues-insys-over-fraudulent-opioid-marketing-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3293042-arizona-ag-sues-insys-over-fraudulent-opioid-marketing-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293041\" data-ts=\"1504207418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293041-iridium-up-after-getting-new-buy-from-drexel-hamilton\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium up after getting new Buy from Drexel Hamilton</a></h4><ul>   <li>Iridium Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc'>IRDM</a>) is in a unique spot for satellite communications, says Drexel Hamilton, which has given the firm a new Buy rating.</li>    <li>Shares are <font color='green'>up 1.9%</font> today after touching their highest point since a 52-week high on June 14, just pennies off that mark.</li>    <li>The company is \"the only global low-earth orbiting satellite network service provider with blanket earth coverage\" and the corresponding ability to offer broad communications services, Drexel says.</li>    <li>The industry is expected to grow from $2B in 2015 to more than $5B by 2025, and Iridium will benefit from several data/communications trends, including the Internet of Things and demands that come from machine-to-machine communications.</li>    <li>The firm has a price target of $14, implying 27% upside from current pricing.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293041\" data-linked=\"Iridium up after getting new Buy from Drexel Hamilton\" data-tweet=\"$IRDM - Iridium up after getting new Buy from Drexel Hamilton https://seekingalpha.com/news/3293041-iridium-up-after-getting-new-buy-from-drexel-hamilton?source=tweet\" data-url=\"https://seekingalpha.com/news/3293041-iridium-up-after-getting-new-buy-from-drexel-hamilton\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293040\" data-ts=\"1504207382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293040-eldorado-mine-arbitration-to-start-in-september\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado mine arbitration to start in September</a></h4><ul>     <li>Greece will <a href=\"http://www.reuters.com/article/us-greece-eldoradogold-arbitration-idUSKCN1BB1XL\" target=\"_blank\">start arbitration next month</a> to settle its differences with Eldorado Gold (<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+3%</font>) over its gold mine development plans in northern Greece, the country's energy minister says.</li>     <li>&ldquo;We have decided to resort to arbitration to stop the tug of war which has been going on for many years and have things cleared up,&rdquo; Energy Minister George Stathakis told Greek state television.</li>     <li>EGO is developing the Skouries and Olympias projects, with the former a particular source of controversy due to differences over testing methods applied to comply with environmental regulations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293040\" data-linked=\"Eldorado mine arbitration to start in September\" data-tweet=\"$EGO - Eldorado mine arbitration to start in September https://seekingalpha.com/news/3293040-eldorado-mine-arbitration-to-start-in-september?source=tweet\" data-url=\"https://seekingalpha.com/news/3293040-eldorado-mine-arbitration-to-start-in-september\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293036\" data-ts=\"1504206057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293036-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PRCP' title='Perceptron, Inc.'>PRCP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293036\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$ZDGE $MRIN $NNDM - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3293036-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293036-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293039\" data-ts=\"1504205995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMP\" target=\"_blank\">MMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293039-magellan-pipeline-restart-allows-texas-city-refinery-to-restart-lipow-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Magellan pipeline restart allows Texas City refinery to restart, Lipow says</a></h4><ul>     <li>Magellan Midstream Partners (<a href='https://seekingalpha.com/symbol/MMP' title='Magellan Midstream Partners, L.P.'>MMP</a> <font color='green'>+1.6%</font>) has <a href=\"https://www.cnbc.com/2017/08/31/gulf-coast-struggles-to-get-gasoline-flowing-as-refineries-remain-shut.html\" target=\"_blank\">restarted a pipeline</a> to Texas City, Tex., from Houston, enabling Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-0.3%</font>) to restart operations at its refinery there, according to oil industry analyst Andy Lipow.</li>     <li>Lack of product has prevented the Explorer pipeline from  transporting fuel from Houston to Tulsa, Okla., and onward to Chicago, Lipow says, although Explorer has restarted deliveries to Dallas; Explorer is owned by Phillips 66 (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-0.1%</font>), Marathon Oil (<a href='https://seekingalpha.com/symbol/MRO' title='Marathon Oil Corporation'>MRO</a> <font color='green'>+2.5%</font>), Sunoco Logistics (ETP <font color='green'>+1.9%</font>) and Shell (<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a>).</li>     <li>Separately, MMP says it has reversed the direction of flow so that Oklahoma refineries can ship product to Dallas.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293039\" data-linked=\"Magellan pipeline restart allows Texas City refinery to restart, Lipow says\" data-tweet=\"$MMP $MMP $MPC - Magellan pipeline restart allows Texas City refinery to restart, Lipow says https://seekingalpha.com/news/3293039-magellan-pipeline-restart-allows-texas-city-refinery-to-restart-lipow-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3293039-magellan-pipeline-restart-allows-texas-city-refinery-to-restart-lipow-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293030\" data-ts=\"1504203694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293030-food-sector-takes-in-campbell-soup-ceos-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Food sector takes in Campbell Soup CEO&#39;s warning</a></h4><ul>     <li>Campbell Soup (<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-7.3%</font>) CEO Denise Morrison called the packaged foods industry \"challenging\" as consumers change their preferences and new competition continues to step in.</li><li>&ldquo;Several variables are at play including value players expanding their presence in the U.S., the growth of store brands and the explosion of e-commerce and meal delivery services disrupting the market,&rdquo; according Morrison. \"We expect conditions to remain hyper competitive for the foreseeable future,\" she warns.</li><li>Kraft Heinz (<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a> <font color='red'>-1.6%</font>), B&amp;G Foods (<a href='https://seekingalpha.com/symbol/BGS' title='B&G Foods, Inc.'>BGS</a> <font color='red'>-1%</font>), Mondelez International (<a href='https://seekingalpha.com/symbol/MDLZ' title='Mondelēz International, Inc.'>MDLZ</a> <font color='red'>-2.3%</font>), Archer Daniels Midland (<a href='https://seekingalpha.com/symbol/ADM' title='Archer Daniels Midland Co.'>ADM</a> <font color='red'>-1.6%</font>), Blue Apron (<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-1.7%</font>) and Conagra Brands (<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='red'>-1%</font>) are all lower as investors eye the frank comments from Campbell's chief.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293030\" data-linked=\"Food sector takes in Campbell Soup CEO&#39;s warning\" data-tweet=\"$CPB $CPB $KHC - Food sector takes in Campbell Soup CEO&#39;s warning https://seekingalpha.com/news/3293030-food-sector-takes-in-campbell-soup-ceos-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3293030-food-sector-takes-in-campbell-soup-ceos-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293029\" data-ts=\"1504203669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293029-jefferies-analyst-names-top-semiconductor-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies analyst names top semiconductor stocks</a></h4><ul><li>Jefferies analyst Mark Lipacis names his top four semiconductor stocks in a note obtained by <a href=\"https://www.cnbc.com/2017/08/31/here-are-4-top-semiconductor-stock-ideas-for-the-next-year-jefferies.html\" target=\"_blank\">CNBC</a>. The winners: Advanced Micro Devices (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+2.3%</font>), Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+1.7%</font>), Smart Global Holdings (<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+4.8%</font>), and Xilinx (<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a> <font color='red'>-0.4%</font>).</li><li>AMD comments: positive reactions to EPYC server MPU following successful Ryzen launch. Checks show EPYC interest from five hyperscale players. Price target: $19.</li><li>NVDA comments: Management confident in data center business, training and inferencing market growth, and moving towards broader deployment of automotive platform. Price target: $180.</li><li>SGH comments: Smartphone mix leaning towards premium, high memory models. ASP growth creates operating leverage. Price target: $23.</li><li>XLNX comments: SDAccel software development environment now in beta at Amazon, which expands number of developers that can access field-programmable gate arrays on the cloud. Price target: $78.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292810-s-and-p-notches-fourth-straight-victory-tech-strength-lifts-nasdaq\" target=\"_blank\">S&amp;P notches fourth straight victory, tech strength lifts Nasdaq</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293029\" data-linked=\"Jefferies analyst names top semiconductor stocks\" data-tweet=\"$AMD $AMD $NVDA - Jefferies analyst names top semiconductor stocks https://seekingalpha.com/news/3293029-jefferies-analyst-names-top-semiconductor-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3293029-jefferies-analyst-names-top-semiconductor-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293026\" data-ts=\"1504202909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSTM\" target=\"_blank\">CSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293026-bloomberg-indian-billionaire-evaluating-bid-for-constellium\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Indian billionaire evaluating bid for Constellium</a></h4><ul>     <li>Dutch aluminum products maker Constellium (<a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color='green'>+6%</font>) is higher following a Bloomberg report that Indian billionaire Kumar Mangalam Birla <a href=\"https://www.bloomberg.com/news/articles/2017-08-31/billionaire-birla-is-said-to-evaluate-constellium-aleris-bids\" target=\"_blank\">may bid for the company</a>, as his conglomerate seeks to grow its aluminum operations overseas.</li><li>The Aditya Birla conglomerate could  decide to pursue an acquisition through Novelis Inc., a unit of Birla's Hindalco Industries, according to the report.</li><li>Bloomberg reported <a href=\"https://seekingalpha.com/news/3285764-bloomberg-constellium-weighing-options-takeover-interest\" target=\"_blank\">earlier this month</a> that CSTM was considering options after drawing takeover interest.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293026\" data-linked=\"Bloomberg: Indian billionaire evaluating bid for Constellium\" data-tweet=\"$CSTM - Bloomberg: Indian billionaire evaluating bid for Constellium https://seekingalpha.com/news/3293026-bloomberg-indian-billionaire-evaluating-bid-for-constellium?source=tweet\" data-url=\"https://seekingalpha.com/news/3293026-bloomberg-indian-billionaire-evaluating-bid-for-constellium\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293025\" data-ts=\"1504202514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293025-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+9%</font>. BBG <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293025\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$EPEG $CLMT $HPR - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3293025-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293025-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293003\" data-ts=\"1504198617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293003-biotechs-lead-charge-ibb-up-2_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs lead the charge, IBB up 2.7%</a></h4><ul><li>Biotechs continue to show strength, leading the market again. Gilead's recent $11.9B takeout of Kite Pharma appears to be a major spark igniting buying. The iShares Nasdaq Biotechnology ETF is up over&nbsp;<font color='green'>9%</font>&nbsp;since last Monday.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+3.1%</font>)(<a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a> <font color='green'>+2.5%</font>)(<a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a> <font color='green'>+2.3%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+2.1%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+3.3%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+3.2%</font>)(<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+6.1%</font>)(<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+10.1%</font>)(<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+1.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293003\" data-linked=\"Biotechs lead the charge, IBB up 2.7%\" data-tweet=\"$GILD $IBB $XBI - Biotechs lead the charge, IBB up 2.7% https://seekingalpha.com/news/3293003-biotechs-lead-charge-ibb-up-2_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3293003-biotechs-lead-charge-ibb-up-2_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292996\" data-ts=\"1504196765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292996-bhp-billiton-downgraded-rbc-on-mature-asset-base\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BHP Billiton downgraded at RBC on mature asset base</a></h4><ul>     <li>BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.5%</font>) is <a href=\"http://www.barrons.com/articles/bhp-billiton-cut-to-underperform-1504172799\" target=\"_blank\">downgraded</a> to Underperform from Sector Perform at RBC on concerns about the impact of the company's mature asset base on medium-term profitability.</li>     <li>RBC&nbsp;likes BHP's decision to exit its U.S. shale business and forecasts sale proceeds of ~$6.2B will snap the balance sheet back inline with peers, but it believes BHP's mature asset base will lead to declining EBITDA relative to diversified mining peers, compounding its view that the stock should not trade at a  premium.</li>     <li>RBC foresees a higher proportion of \"life extension\" capex spending vs. more \"growth\" spending in peers, which will require more capital to be spent in the future and for shares to trade at higher free cash yields to compensate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292996\" data-linked=\"BHP Billiton downgraded at RBC on mature asset base\" data-tweet=\"$BHP - BHP Billiton downgraded at RBC on mature asset base https://seekingalpha.com/news/3292996-bhp-billiton-downgraded-rbc-on-mature-asset-base?source=tweet\" data-url=\"https://seekingalpha.com/news/3292996-bhp-billiton-downgraded-rbc-on-mature-asset-base\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292995\" data-ts=\"1504196647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292995-astrazeneca-trumpets-full-slate-of-presentations-esmo-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca trumpets full slate of presentations at ESMO; shares up 2%</a></h4><ul><li>AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1.8%</font>) <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esmo-2017-congress-31082017.html\" target=\"_blank\">announces </a>that there will be more than 40 presentations related to its currently approved and under-development product portfolio at the European Society of Medical Oncology &#40;ESMO&#41; Congress in Madrid, September 8-12.</li><li>Key events:</li><li>Results from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02125461?intr=Durvalumab&amp;titles=pacific&amp;phase=2&amp;rank=1\" target=\"_blank\">PACIFIC </a>study evaluating <a href=\"https://www.imfinzi.com/\" target=\"_blank\">Imfinzi </a>(durvalumab) in patients with locally advanced unresectable non-small cell lung cancer &#40;NSCLC&#41; following chemo. The study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival &#40;PFS&#41;, a clinical setting with no currently approved treatments (Saturday, Sept. 9).</li><li>Results from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02296125?intr=osimertinib&amp;titles=flaura&amp;phase=2&amp;rank=1\" target=\"_blank\">FLAURA </a>study assessing Tagrisso (osimertinib) versus standard-of-care treatment with erlotinib (Roche's <a href=\"http://www.tarceva.com/patient/\" target=\"_blank\">Tarceva</a>) or genfitinib (<a href=\"https://www.iressa-usa.com/?source=ISA_D_C_1&amp;umedium=CPC&amp;uadpub=Google&amp;ucampaign=IressaDTCBranded-General&amp;ucreative=Branded-Alone-EX&amp;uplace=gefitinib&amp;cmpid=1\" target=\"_blank\">Iressa</a>) in first-line EGFR-positive NSCLC patients. The study demonstrated a statistically significant and clinically meaningful improvement in PFS (Saturday, Sept. 9).</li></ul><div class=\"tiny-share-widget\" data-id=\"3292995\" data-linked=\"AstraZeneca trumpets full slate of presentations at ESMO; shares up 2%\" data-tweet=\"$AZN - AstraZeneca trumpets full slate of presentations at ESMO; shares up 2% https://seekingalpha.com/news/3292995-astrazeneca-trumpets-full-slate-of-presentations-esmo-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3292995-astrazeneca-trumpets-full-slate-of-presentations-esmo-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292989\" data-ts=\"1504195344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292989-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MSN' title='Emerson Radio Corp'>MSN</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292989\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$REED $CYRX $WPRT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3292989-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292989-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292983\" data-ts=\"1504194291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMC\" target=\"_blank\">FMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292983-fmc-corp-hiked-to-buy-from-sell-bofa-ag-outlook-seen-improving\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FMC Corp. hiked to Buy from Sell at BofA as ag outlook seen improving</a></h4><ul>     <li>FMC Corp. (<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a> <font color='green'>+2.5%</font>) is <a href=\"http://thefly.com/thestreet/realmoney/index.php/FMCid2603152/FMC-FMC-Corporation-upgraded-to-Buy-from-Underperform-at-BofAMerrill\" target=\"_blank\">upgraded two notches to Buy</a> from Underperform with a Street-hgih $103 price target, up from $65, at BofA Merrill Lynch, which cites survey results that indicate ag sales are likely to increase 1%-3% rather than decline 1%-3% as previously expected.</li>     <li>BofA believes FMC will be a structurally improved business following the acquisition of assets from DuPont that doubles ag EBITDA and further diversifies earnings, especially if the use of competing product dicamba is restricted.</li>     <li>The firm thinks can beat consensus 2018-19 estimates by 10%-15% from ag growth volume acceleration, DuPont synergies and higher prices and volume in lithium.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292983\" data-linked=\"FMC Corp. hiked to Buy from Sell at BofA as ag outlook seen improving\" data-tweet=\"$FMC - FMC Corp. hiked to Buy from Sell at BofA as ag outlook seen improving https://seekingalpha.com/news/3292983-fmc-corp-hiked-to-buy-from-sell-bofa-ag-outlook-seen-improving?source=tweet\" data-url=\"https://seekingalpha.com/news/3292983-fmc-corp-hiked-to-buy-from-sell-bofa-ag-outlook-seen-improving\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292982\" data-ts=\"1504194261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCOM\" target=\"_blank\">BCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292982-b-communications-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B Communications reports Q2 results</a></h4><ul><li>B Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/BCOM' title='B Communications Ltd.'>BCOM</a>): Q2 EPS of NIS0.13</li><li>Revenue of NIS2.46B (-2.0% Y/Y)</li><li>Shares <font color='green'>+4.26%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16928758-b-communications-reports-financial-results-second-quarter-2017\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292982\" data-linked=\"B Communications reports Q2 results\" data-tweet=\"$BCOM - B Communications reports Q2 results https://seekingalpha.com/news/3292982-b-communications-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3292982-b-communications-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292979\" data-ts=\"1504193534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMTX\" target=\"_blank\">DMTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292979-dosing-finding-study-commences-for-dimension-therapeutics-gene-therapy-candidate-dtx301-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dosing-finding study commences for Dimension Therapeutics&#39; gene therapy candidate DTX301 in patients with urea cycle disorder; shares up 2%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16928321-dimension-therapeutics-commences-patient-dosing-global-multi-center-phase-1-2-clinical-trial\" target=\"_blank\">Patient dosing</a> is underway in a <a href=\"https://clinicaltrials.gov/show/NCT02991144\" target=\"_blank\">Phase 1/2</a> open-label, dose-finding trial assessing Dimension Therapeutics' (<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='green'>+2.4%</font>) DTX301 in patients with Ornithine Transcarbamylase Deficiency, a genetic urea cycle disorder characterized by the buildup of ammonia in the blood.</li><li>The primary endpoint is safety as measured by the incidence of treatment-emergent adverse events. Secondary endpoints include efficacy measures of the change from baseline in ureagenesis rate and the change from baseline in the 24-hour area-under-the-curve of ammonia. According to ClinicalTrials.gov, the estimated primary completion date is November 2018.</li><li>DTX301 is an AAV gene therapy product designed to deliver ornithine transcarbamylase gene expression in a sustainable way.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291791-regenxbio-acquire-dimension-therapeutics-stock-deal-dimension-163-percent-premarket\" target=\"_blank\">REGENXBIO to acquire Dimension Therapeutics in all-stock deal, Dimension up 163% premarket</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292979\" data-linked=\"Dosing-finding study commences for Dimension Therapeutics&#39; gene therapy candidate DTX301 in patients with urea cycle disorder; shares up 2%\" data-tweet=\"$DMTX - Dosing-finding study commences for Dimension Therapeutics&#39; gene therapy candidate DTX301 in patients with urea cycle disorder; shares up 2% https://seekingalpha.com/news/3292979-dosing-finding-study-commences-for-dimension-therapeutics-gene-therapy-candidate-dtx301-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3292979-dosing-finding-study-commences-for-dimension-therapeutics-gene-therapy-candidate-dtx301-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292976\" data-ts=\"1504192223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292976-impax-labs-breaks-out-up-18-on-bullish-volume-generic-drug-firms-up-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Impax Labs breaks out, up 18% on bullish volume, generic drug firms up in early trading</a></h4><ul><li>Impax Laboratories (IPXL <font color='green'>+17.5%</font>) breaks out of short-term consolidation on increased volume, leading leading generic drug makers.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+2.4%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+3.1%</font>)(VRX <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a> <font color='green'>+3.5%</font>)(<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>)(<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='green'>+2.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292976\" data-linked=\"Impax Labs breaks out, up 18% on bullish volume, generic drug firms up in early trading\" data-tweet=\"$AMRX $AMRX $MYL - Impax Labs breaks out, up 18% on bullish volume, generic drug firms up in early trading https://seekingalpha.com/news/3292976-impax-labs-breaks-out-up-18-on-bullish-volume-generic-drug-firms-up-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3292976-impax-labs-breaks-out-up-18-on-bullish-volume-generic-drug-firms-up-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292948\" data-ts=\"1504191722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292948-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> IPXL <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/NK' title='NantKwest'>NK</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292948\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$AMRX $MNKD $QTNT - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3292948-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3292948-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292970\" data-ts=\"1504191573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMDZ\" target=\"_blank\">IMDZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292970-interim-data-positive-for-immune-designs-prime-boost-vaccine-candidate-cmb305-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interim data positive for Immune Design&#39;s prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16928012-immune-design-announces-new-cmb305-checkpoint-inhibitor-topline-data-upcoming-presentation\" target=\"_blank\">Interim top-line data</a> from a Phase 2 clinical trial assessing the combination of Immune Design's&nbsp;(<a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='green'>+4.5%</font>)&nbsp;CMB305 and Roche's TECENTRIQ (atezolizumab) compared to TECENTRIQ alone in 88 soft tissue sarcoma patients showed a treatment effect from CMB305. The results will be presented at ESMO in Madrid on September 11.</li><li>Data on the first 36 patients demonstrated a clinical benefit from the inclusion of CMB305 as measured by disease control rate, progression-free survival and time-to-next treatment. Patients in the CMB305 cohort also showed a higher frequency of induced immune responses to a tumor antigen called <a href=\"https://en.wikipedia.org/wiki/NY-ESO-1\" target=\"_blank\">NY-ESO-1</a>.</li><li><a href=\"http://www.immunedesign.com/pipeline/\" target=\"_blank\">CMB305 </a>is a prime-boost vaccine against NY-ESO-1-expressing tumors designed to generate an integrated anti-NY-ESO-1 response via its specific interaction with messengers between the innate and adaptive immune systems called <a href=\"https://en.wikipedia.org/wiki/Dendritic_cell\" target=\"_blank\">dendritic cells</a>. The company says its approach is different from other cancer vaccines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292970\" data-linked=\"Interim data positive for Immune Design&#39;s prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5%\" data-tweet=\"$IMDZ - Interim data positive for Immune Design&#39;s prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5% https://seekingalpha.com/news/3292970-interim-data-positive-for-immune-designs-prime-boost-vaccine-candidate-cmb305-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3292970-interim-data-positive-for-immune-designs-prime-boost-vaccine-candidate-cmb305-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292969\" data-ts=\"1504190401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292969-amd-launching-budget-friendly-ryzen-threadripper-1900x\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD launching budget-friendly Ryzen Threadripper 1900X</a></h4><ul><li>        Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) announces a new Ryzen Threadripper 1900X processor with a budget price of $549, according to <a href=\"http://www.techradar.com/news/amd-releases-budget-8-core-ryzen-threadripper-1900x-processor\" target=\"_blank\">TechRadar</a>.</li><li>           The 8 core/16 thread 1900x clocks at 3.8GHz or turbo clocks at 4.0GHz with an XFR boost to 4.2GHz. </li><li> The pricing is in the ballpark of the 8 core/16 thread Ryzen 7 1800X, which retails for $499 but well below the $799 12 core/24 thread Threadripper 1920X or $999 16 core/32 thread Threadripper 1950X. </li><li> AMD shares are&nbsp;<font color='green'>up 2.68%</font>.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3292066-amd-baidu-announce-data-center-collaboration\" target=\"_blank\">AMD and Baidu announce data center collaboration</a> (Aug. 28)  </li></ul><div class=\"tiny-share-widget\" data-id=\"3292969\" data-linked=\"AMD launching budget-friendly Ryzen Threadripper 1900X\" data-tweet=\"$AMD - AMD launching budget-friendly Ryzen Threadripper 1900X https://seekingalpha.com/news/3292969-amd-launching-budget-friendly-ryzen-threadripper-1900x?source=tweet\" data-url=\"https://seekingalpha.com/news/3292969-amd-launching-budget-friendly-ryzen-threadripper-1900x\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292966\" data-ts=\"1504189833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292966-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+30 Bcf</strong> vs. +32 Bcf consensus, +43 Bcf last week.</li><li>Futures&nbsp;<font color='red'>-0.10%</font>&nbsp;to $2.936.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292966\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3292966-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3292966-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>98&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292960\" data-ts=\"1504188420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCVL\" target=\"_blank\">SCVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292960-strong-rally-for-shoe-carnival-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong rally for Shoe Carnival after earnings</a></h4><ul> <li>Shoe Carnival (<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color='green'>+22.7%</font>) soars after the retailer tops Q2 estimates and issues upside guidance. Comparable sales were up 0.4% during the quarter.</li> <li>The company sees full year sales of $1.01B to $1.02B vs. $1.0B consensus and Full year EPS of $1.35 to $1.45 vs. $1.37 consensus.</li> <li>\"We believe we are well positioned for back-to-school with a trend-right assortment of branded, family footwear, favorable inventory position, and our multi-channel initiatives which have already generated an August comparable store sales increase of 7.0 percent,\" updates CEO Cliff Sifford.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292774-shoe-carnival-beats-0_04-beats-revenue\" target=\"_blank\">Shoe Carnival beats by $0.04, beats on revenue</a> (Aug. 30)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292960\" data-linked=\"Strong rally for Shoe Carnival after earnings\" data-tweet=\"$SCVL - Strong rally for Shoe Carnival after earnings https://seekingalpha.com/news/3292960-strong-rally-for-shoe-carnival-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3292960-strong-rally-for-shoe-carnival-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292949\" data-ts=\"1504187684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXTR\" target=\"_blank\">DXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292949-fda-clears-expanded-use-of-dexteras-microcutter-5-80-shares-up-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears expanded use of Dextera&#39;s MicroCutter 5/80; shares up 20%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16928392-dextera-surgical-receives-expanded-indication-solid-organ-surgery-microcutter-5-80\" target=\"_blank\">grants 510(k) clearance</a> for Dextera Surgical's (<a href='https://seekingalpha.com/symbol/DXTR' title='Dextera Surgical Inc.'>OTC:DXTR</a> <font color='green'>+20.4%</font>) MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip White Reloads for use in open solid organ parenchymal dissection techniques, including the liver, kidney, pancreas and spleen.</li><li>Stanford University Medical Center associate professor of surgery Brendan Visser, M.D., says, &ldquo;The small size and large degree of articulation provided by the <a href=\"https://www.dexterasurgical.com/microcutter-580/\" target=\"_blank\">MicroCutter 5/80</a> is especially beneficial in maneuvering within the confined spaces around solid internal organs. In addition, with the small footprint of the MicroCutter&rsquo;s jaws, I&rsquo;m able to successfully operate with less dissection.&rdquo;</li><li>The expanded indication represents an additional 44K procedures in the U.S. each year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292949\" data-linked=\"FDA clears expanded use of Dextera&#39;s MicroCutter 5/80; shares up 20%\" data-tweet=\"$DXTR - FDA clears expanded use of Dextera&#39;s MicroCutter 5/80; shares up 20% https://seekingalpha.com/news/3292949-fda-clears-expanded-use-of-dexteras-microcutter-5-80-shares-up-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3292949-fda-clears-expanded-use-of-dexteras-microcutter-5-80-shares-up-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292943\" data-ts=\"1504187025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292943-vistagen-prices-stock-offering-1_75-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VistaGen prices stock offering at $1.75; shares down 7%</a></h4><ul><li>VistaGen Therapeutics (<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='red'>-6.6%</font>) <a href=\"https://seekingalpha.com/pr/16928545-vistagen-announces-pricing-underwritten-offering-common-stock-warrants-purchase-common-stock\" target=\"_blank\">prices </a>its public offering of 1,371,430 shares of common stock and warrants to purchase up to 1,892,572 shares of common at a combined price of $1.75.</li><li>Each common share is being offered with 1.0128 Series A1 Warrants and 0.3672 of a Series A2 Warrant. Each complete five-year warrant is exercisable at $1.82 per common share.</li><li>Gross proceeds should be ~$2.4M. Closing date is September 6.</li><li>Net proceeds will be used for general corporate purposes.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292943\" data-linked=\"VistaGen prices stock offering at $1.75; shares down 7%\" data-tweet=\"$VTGN - VistaGen prices stock offering at $1.75; shares down 7% https://seekingalpha.com/news/3292943-vistagen-prices-stock-offering-1_75-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3292943-vistagen-prices-stock-offering-1_75-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292946\" data-ts=\"1504186992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TITN\" target=\"_blank\">TITN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292946-on-titan-machinerys-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Titan Machinery&#39;s Q2</a></h4><ul>     <li>Titan Machinery (NASDAQ:<a href='https://seekingalpha.com/symbol/TITN' title='Titan Machinery Inc.'>TITN</a>) reports equipment revenue declined 3.1% to $167.9M in <a href=\"https://seekingalpha.com/pr/16928175-titan-machinery-inc-announces-results-fiscal-second-quarter-ended-july-31-2017\" target=\"_blank\">Q2</a>.</li>     <li>Parts revenue slipped 4.6% to $55.6M and service revenue -2.6% to $30.5M.</li>     <li>Segment revenue: Agriculture: $138.5M (-9.9%); Construction: $77.9M (-6.3%); International: $52.4M (+26.3%).</li>     <li>Gross margin rate improved 60 bps to 19.6%.</li>     <li>Operating expense rate up 20 bps to 18.7%.</li>     <li><b>FY2018 Guidance</b>:&nbsp;Agriculture sales: -10% to -15%;&nbsp;Construction sales: -5% to -10%;&nbsp;International sales: +20% to +25%; Equipments margins: 7% to 7.5%; Diluted EPS: -$0.15 to -$0.35.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3292946\" data-linked=\"More on Titan Machinery&#39;s Q2\" data-tweet=\"$TITN - More on Titan Machinery&#39;s Q2 https://seekingalpha.com/news/3292946-on-titan-machinerys-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3292946-on-titan-machinerys-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292941\" data-ts=\"1504186269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAG\" target=\"_blank\">AMAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292941-fda-accepts-amags-application-for-expanded-use-of-feraheme-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts AMAG&#39;s application for expanded use of Feraheme; shares ahead 2% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16928322-amag-announces-u-s-fda-filing-acceptance-six-month-review-feraheme-ferumoxytol-treatment\" target=\"_blank\">accepts for review</a> AMAG Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a>) supplemental New Drug Application (sNDA) seeking approval for Feraheme (ferumoxytol) for the treatment of all adults with iron deficiency anemia &#40;IDA&#41;&nbsp;who are intolerant of or do not respond adequately to oral iron therapy. The agency's action date is February 2, 2018.</li><li>The FDA approved Feraheme in June 2009 for the treatment of IDA in adults with chronic kidney disease.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292941\" data-linked=\"FDA accepts AMAG&#39;s application for expanded use of Feraheme; shares ahead 2% premarket\" data-tweet=\"$AMAG - FDA accepts AMAG&#39;s application for expanded use of Feraheme; shares ahead 2% premarket https://seekingalpha.com/news/3292941-fda-accepts-amags-application-for-expanded-use-of-feraheme-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292941-fda-accepts-amags-application-for-expanded-use-of-feraheme-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292939\" data-ts=\"1504186029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOMO\" target=\"_blank\">MOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292939-momoplus-4_5-yyplus-3_5-on-new-goldman-buy-launches\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momo +4.5%, YY +3.5% on new Goldman Buy launches</a></h4><ul>    <li>Momo (NASDAQ:<a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a>) is <font color='green'>up 4.5%</font>, building on yesterday's 5.8% gain, and YY (NASDAQ:<a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a>) is <font color='green'>up 3.5%</font> premarket, after Goldman Sachs gave the two new Buy ratings.</li>    <li>They're the \"leaders of China's live streaming sector,\" the firm says, a market that it estimates to grow to $15B by 2020 from $2B in 2015.</li>    <li>Goldman joins some well established bulls on both companies, each with more than a dozen Buy ratings from Street analysts. It's set a price target of $56 for <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> (implying 55% upside).</li>    <li>Meanwhile, it has a price target of $101 for YY, implying 42% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292939\" data-linked=\"Momo +4.5%, YY +3.5% on new Goldman Buy launches\" data-tweet=\"$MOMO $MOMO $YY - Momo +4.5%, YY +3.5% on new Goldman Buy launches https://seekingalpha.com/news/3292939-momoplus-4_5-yyplus-3_5-on-new-goldman-buy-launches?source=tweet\" data-url=\"https://seekingalpha.com/news/3292939-momoplus-4_5-yyplus-3_5-on-new-goldman-buy-launches\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292935\" data-ts=\"1504185286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292935-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+17%</font>&nbsp;as <a href=\"https://seekingalpha.com/pr/16928277-nxt-id-subsidiary-fitpay-power-garmin-pay-garmin-vivoactive-3-smartwatch\" target=\"_blank\">Fitpay</a> power Garmin pay on Garmin vivoactive 3 smartwatch.</li><li>APRI <font color='green'>+8%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3292915-fda-accepts-apricus-bios-resubmitted-vitaros-nda-action-date-february-17-shares-6-percent\" target=\"_blank\">announcement&nbsp;</a>that the FDA has accepted its resubmitted New Drug Application &#40;NDA&#41; for Vitaros (alprostadil).</li><li><a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292935\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$NXTD $SEEL $OTIC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3292935-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292935-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292934\" data-ts=\"1504185239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292934-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>&nbsp;<font color='red'>-22%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292773-dryships-reports-q2-results\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292798-semtech-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>&nbsp;<font color='red'>-7%</font>&nbsp;on weak <a href=\"https://seekingalpha.com/news/3292887-ciena-beats-q2-estimates-issues-weak-guidance-shares-8_6-percent\" target=\"_blank\">guidance</a>.</li><li><a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292881-campbell-soup-misses-0_03-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3292866-genesco-misses-0_02-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292934\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$DRYS $SMTC $FSNN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3292934-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292934-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292932\" data-ts=\"1504185073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MACK\" target=\"_blank\">MACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292932-merrimack-pharma-1-10-reverse-split-effective-september-6-shares-down-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merrimack Pharma 1:10 reverse split effective September 6; shares down 10%</a></h4><ul><li>Merrimack Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a>) slips&nbsp;<font color='red'>10%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16928294-merrimack-announces-date-one-ten-reverse-stock-split\" target=\"_blank\">announcement </a>that its previously disclosed 1:10 reverse split of its common stock will be effective September 5. Post-split trading will commence on September 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292932\" data-linked=\"Merrimack Pharma 1:10 reverse split effective September 6; shares down 10%\" data-tweet=\"$MACK - Merrimack Pharma 1:10 reverse split effective September 6; shares down 10% https://seekingalpha.com/news/3292932-merrimack-pharma-1-10-reverse-split-effective-september-6-shares-down-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3292932-merrimack-pharma-1-10-reverse-split-effective-september-6-shares-down-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292919\" data-ts=\"1504183859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LE\" target=\"_blank\">LE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292919-margins-tighten-lands-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Margins tighten at Lands&#39; End</a></h4><ul> <li>Lands' End (NASDAQ:<a href='https://seekingalpha.com/symbol/LE' title='Lands&#39; End, Inc.'>LE</a>) reports comparable sales rose 3.8% in <a href=\"https://seekingalpha.com/pr/16928173-lands-end-announces-second-quarter-fiscal-2017-results\" target=\"_blank\">Q2</a>.</li> <li>Retail segment revenue decreased 7.4% to $42.2M as a lower store count factored in.</li> <li>Gross margin fell to 44.4% of sales from 46.6% a year ago. Analysts expected a mark of 45.9%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292864-lands-end-misses-0_03-beats-revenue\" target=\"_blank\">Lands' End misses by $0.03, beats on revenue</a> (Aug. 31)</li> <li>Shares of Lands' End are <font color='green'>up 0.72%</font> to $13.95 in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292919\" data-linked=\"Margins tighten at Lands&#39; End\" data-tweet=\"$LE - Margins tighten at Lands&#39; End https://seekingalpha.com/news/3292919-margins-tighten-lands-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3292919-margins-tighten-lands-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292915\" data-ts=\"1504183262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEEL\" target=\"_blank\">SEEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292915-fda-accepts-apricus-bios-resubmitted-vitaros-nda-action-date-february-17-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Apricus Bio&#39;s resubmitted Vitaros NDA, action date February 17; shares up 6% premarket</a></h4><ul><li>Nano cap Apricus Biosciences (APRI) perks up&nbsp;<font color='green'>6%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16928213-apricus-biosciences-announces-fda-acknowledgement-vitaros-class-2-nda-resubmission\" target=\"_blank\">announcement </a>that the FDA has accepted its resubmitted New Drug Application &#40;NDA&#41; for Vitaros (alprostadil), an on-demand topical cream for the treatment of erectile dysfunction.&nbsp;The agency's action date is February 17, 2018.</li><li>The company received a CRL in 2008 in response to its original filing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3225743-apricus-bio-expects-resubmit-vitaros-nda-next-year-now-considered-drug-device-combination\" target=\"_blank\">Apricus Bio expects to resubmit Vitaros NDA next year; now considered drug-device combination; shares down 22% premarket</a> (Nov. 18, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292915\" data-linked=\"FDA accepts Apricus Bio&#39;s resubmitted Vitaros NDA, action date February 17; shares up 6% premarket\" data-tweet=\"$SEEL - FDA accepts Apricus Bio&#39;s resubmitted Vitaros NDA, action date February 17; shares up 6% premarket https://seekingalpha.com/news/3292915-fda-accepts-apricus-bios-resubmitted-vitaros-nda-action-date-february-17-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3292915-fda-accepts-apricus-bios-resubmitted-vitaros-nda-action-date-february-17-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292907\" data-ts=\"1504182513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STDY\" target=\"_blank\">STDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292907-fda-rejects-steaymeds-marketing-application-for-lead-candidate-trevyent-for-pah-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects SteayMed&#39;s marketing application for lead candidate Trevyent for PAH; shares down 28% premarket</a></h4><ul><li>Thinly traded micro cap SteadyMed (NASDAQ:<a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a>) slumps&nbsp;<font color='red'>28%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16928174-steadymed-receives-refusal-file-letter-fda-trevyent-new-drug-application\" target=\"_blank\">announcement </a>that received a Refusal to File letter from the FDA regarding its New Drug Application &#40;NDA&#41; seeking approval for Trevyent for the treatment of pulmonary arterial hypertension &#40;PAH&#41;.</li><li>A Refusal to File letter means that the application was not complete enough to allow for review. In this case, the FDA requested additional information on certain device specifications and performance testing as well as additional design verification and validation testing on the final product.</li><li>The company has requested a Type A meeting with the agency to clarify the information it needs to accept the filing.</li><li><a href=\"http://www.steadymed.com/portfolio/trevyent.php\" target=\"_blank\">Trevyent</a>&nbsp;is a small, pre-filled, single-use device that delivers parenteral treprostinil (United Therapeutics'&nbsp;<a href=\"https://www.remodulin.com/\" target=\"_blank\">Remodulin</a>) at a pre-programmed rate to PAH patients. Its value proposition is a more convenient dosing regimen than Remodulin, which requires weekly infusions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292907\" data-linked=\"FDA rejects SteayMed&#39;s marketing application for lead candidate Trevyent for PAH; shares down 28% premarket\" data-tweet=\"$STDY - FDA rejects SteayMed&#39;s marketing application for lead candidate Trevyent for PAH; shares down 28% premarket https://seekingalpha.com/news/3292907-fda-rejects-steaymeds-marketing-application-for-lead-candidate-trevyent-for-pah-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3292907-fda-rejects-steaymeds-marketing-application-for-lead-candidate-trevyent-for-pah-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292905\" data-ts=\"1504181811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292905-barnes-noble-rallies-on-sale-intrigue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble rallies on sale intrigue</a></h4><ul> <li>Banres &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) is working with Guggenhein in talking to potential suitors, according to DealReporter.</li> <li>Apollo Global Management and Platinum Equity are two of the private equity firms said to have talked to the retailer.</li> <li>Shares of Barnes &amp; Noble are <font color='green'>up 4.83%</font> premarket to $7.60.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292905\" data-linked=\"Barnes &amp; Noble rallies on sale intrigue\" data-tweet=\"$BKS - Barnes &amp; Noble rallies on sale intrigue https://seekingalpha.com/news/3292905-barnes-noble-rallies-on-sale-intrigue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292905-barnes-noble-rallies-on-sale-intrigue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292901\" data-ts=\"1504181196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292901-campbell-soup-falls-sales-pressures-mount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Campbell Soup falls as sales pressures mount</a></h4><ul> <li>Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) trades lower after citing sales pressure.</li> <li>\"The operating environment for the packaged foods industry remains challenging due to shifting demographics, changing consumer preferences for food, the adoption of new shopping behaviors and the dynamic retailer landscape. In these times, sales growth remains a challenge.\" says CEo Denise Morrison.</li> <li>Organic sales fell 1% during <a href=\"https://seekingalpha.com/pr/16928247-campbell-reports-fourth-quarter-full-year-results\" target=\"_blank\">FQ4</a>. Gross margin improved to 36.9% of sales from 36.1% a year ago as cost savings initiatives kicked in. Marketing and selling expenses decreased 34% to $143M during the quarter.</li> <li>The food company sets FY18 revenue guidance at $7.73B to $7.89B vs. $8.02B and FY18 EPS guidance at $3.04 to $3.31 vs. $3.20 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292881-campbell-soup-misses-0_03-misses-revenue\" target=\"_blank\">Campbell Soup misses by $0.03, misses on revenue</a> (Aug. 31)</li> <li>CPB <font color='red'>-4.83%</font> premarket to $47.83.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292901\" data-linked=\"Campbell Soup falls as sales pressures mount\" data-tweet=\"$CPB - Campbell Soup falls as sales pressures mount https://seekingalpha.com/news/3292901-campbell-soup-falls-sales-pressures-mount?source=tweet\" data-url=\"https://seekingalpha.com/news/3292901-campbell-soup-falls-sales-pressures-mount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292899\" data-ts=\"1504180947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BVXV\" target=\"_blank\">BVXV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292899-biondvax-pharma-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biondvax Pharma reports Q2 results</a></h4><ul><li>Biondvax Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BVXV' title='Biondvax Pharmaceuticals'>BVXV</a>) <a href=\"https://seekingalpha.com/pr/16928266-biondvax-provides-second-quarter-2017-financial-results-update\" target=\"_blank\">Q2 results</a> &#40;NIS&#41;: Revenues: 0; R&amp;D Expense: 2M (+33.3%); SG&amp;A: 0.6M (-40.0%); Operating Loss: (2.6M) (-4.0%); Net Loss: (11.7M); Loss Per Share: (0.07); Quick Assets: 36.6M (+28.0%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292899\" data-linked=\"Biondvax Pharma reports Q2 results\" data-tweet=\"$BVXV - Biondvax Pharma reports Q2 results https://seekingalpha.com/news/3292899-biondvax-pharma-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3292899-biondvax-pharma-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292894\" data-ts=\"1504180497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BVXV\" target=\"_blank\">BVXV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292894-biondvax-pharmaceuticals-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biondvax Pharmaceuticals reports Q2 results</a></h4><ul><li>Biondvax&nbsp;Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BVXV' title='Biondvax Pharmaceuticals'>BVXV</a>): Q2 EPS of -NIS0.07</li><li>Shares <font color='green'>+6.35%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16928266-biondvax-provides-second-quarter-2017-financial-results-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3292894\" data-linked=\"Biondvax Pharmaceuticals reports Q2 results\" data-tweet=\"$BVXV - Biondvax Pharmaceuticals reports Q2 results https://seekingalpha.com/news/3292894-biondvax-pharmaceuticals-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3292894-biondvax-pharmaceuticals-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292889\" data-ts=\"1504179613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GCO\" target=\"_blank\">GCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292889-genesco-lowers-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genesco lowers profit guidance</a></h4><ul> <li>Genesco (NYSE:<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a>) slides after some sales pressure in <a href=\"https://seekingalpha.com/pr/16928179-genesco-reports-second-quarter-fiscal-2018-results\" target=\"_blank\">Q2</a> and a painful cut in profit guidance.</li> <li>Comparable sales were flat during the quarter. Comparable sales for the Schuh business were up 3%, while Johnson &amp; Murphy saw comparable sales fall 1%.</li> <li>E-commerce sales were up 30% Y/Y during the quarter.</li> <li>The second quarter was a bit more challenging than we expected, as positive momentum at Journeys was offset by increasing headwinds at Lids. Journeys comps improved significantly, as we emerged from the latest fashion cycle,\" notes CEO Robert Dennis.</li> <li>Looking ahead, Genesco sees FY18 EPS of $3.35 to $3.65 vs. $3.90 to $4.05 prior and $3.72 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292866-genesco-misses-0_02-misses-revenue\" target=\"_blank\">Genesco misses by $0.02, misses on revenue</a> (Aug. 31)</li> <li>GCO <font color='red'>-9.80%</font> premarket to $23.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292889\" data-linked=\"Genesco lowers profit guidance\" data-tweet=\"$GCO - Genesco lowers profit guidance https://seekingalpha.com/news/3292889-genesco-lowers-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3292889-genesco-lowers-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292887\" data-ts=\"1504178856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292887-ciena-beats-q2-estimates-issues-weak-guidance-shares-down-8_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ciena beats Q2 estimates, issues weak guidance; shares down 8.6%</a></h4><ul><li>           Ciena (NASDAQ:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) shares are&nbsp;<font color='red'>down 8.6%</font>&nbsp;premarket after reporting Q3 earnings with narrow EPS and revenue beats. The Q4 guidance came in under consensus with revenue expected from $720M to $750M compared to the $770.3M analyst estimate. Gross margin expected in the mid-40s percentage range and operating expenses at $240M.&nbsp; </li><li> Segment revenue: Networking Platforms, $592.3M (+10%); Software and Software-Related Services, $42.3M (+34%); Global Services, (-4%). </li><li> U.S. customers contributed 60.1% of overall revenue and two customers each accounted for more than 10% of revenue. </li><li> Adjusted gross margin was 45.5% compared to 45.7% in Q2 and 46.8% in the prior year&rsquo;s quarter. Adjusted operating margin was 14.1% compared to 12.5% in Q2 and 13.5% last year. Cash flow from operations totaled $50.6M and Ciena ended the quarter with $559.5M in cash and equivalents. </li><li> <a href=\"https://seekingalpha.com/pr/16928214-ciena-reports-fiscal-third-quarter-2017-financial-results\" target=\"_blank\">Press release</a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3292868-ciena-beats-0_02-beats-revenue\" target=\"_blank\">Ciena beats by $0.02, beats on revenue</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292887\" data-linked=\"Ciena beats Q2 estimates, issues weak guidance; shares down 8.6%\" data-tweet=\"$CIEN - Ciena beats Q2 estimates, issues weak guidance; shares down 8.6% https://seekingalpha.com/news/3292887-ciena-beats-q2-estimates-issues-weak-guidance-shares-down-8_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3292887-ciena-beats-q2-estimates-issues-weak-guidance-shares-down-8_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292885\" data-ts=\"1504178493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DG\" target=\"_blank\">DG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292885-sales-track-higher-dollar-general\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sales track higher at Dollar General</a></h4><ul> <li>Dollar General (NYSE:<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a>) shoots higher after topping sales estimates with its <a href=\"https://seekingalpha.com/pr/16928180-dollar-general-corporation-reports-second-quarter-2017-financial-results\" target=\"_blank\">Q2 report</a>.</li> <li>Comparable sales rose 2.6% during the quarter vs. +1.6% consensus estimate. Traffic and average transaction amount were both higher during the quarter.</li> <li>Gross margin was down 10 bps to 30.7% of sales. SG&amp;A expenses rose 60 bps to 22.3% of sales.</li> <li>The retailer ended the quarter with an inventory position down 1% Y/Y on a per store basis to $3.46B.</li> <li>Looking ahead, Dollar General expects sales to increase 5% to 7% for the full year and sees EPS of $4.35 to $4.50 vs. $4.25 to $4.50 prior and $4.48 consensus. \"In a dynamic retail and consumer landscape, we continue to make targeted investments in our business to execute on our focused strategic and operating initiatives which we believe will contribute to sustainable improvement over time,\" says CEO Todd Vasos.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292867-dollar-general-misses-0_03-beats-revenue\" target=\"_blank\">Dollar General misses by $0.03, beats on revenue</a> (Aug. 31)</li> <li>Shares of Dollar General are&nbsp;<font color='green'>up 1.66%</font>&nbsp;premarket to $78.00 vs. a 52-week trading range of $65.97 to $80.67.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292885\" data-linked=\"Sales track higher at Dollar General\" data-tweet=\"$DG - Sales track higher at Dollar General https://seekingalpha.com/news/3292885-sales-track-higher-dollar-general?source=tweet\" data-url=\"https://seekingalpha.com/news/3292885-sales-track-higher-dollar-general\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292883\" data-ts=\"1504178347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292883-astrazeneca-tried-to-buy-daiichi-sankyo-last-year-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca tried to buy Daiichi Sankyo last year - report</a></h4><ul><li>The online version of Nikkei Business reported yesterday that AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) <a href=\"http://www.reuters.com/article/us-health-sleep-dementia-idUSKCN1BA2C3\" target=\"_blank\">made a bid</a> for Daiichi Sankyo (<a href='https://seekingalpha.com/symbol/DSKYF' title='Daiichi Sankyo Co., Ltd.'>OTCPK:DSKYF</a>) last year, triggering a 13% spike in the latter's share price and triggering a trading halt. Daiichi, valued at $16B, declined the offer.</li><li>The companies have been working together for some time, including a 2010 agreement to supply and promote Nexium in Japan and a 2015 deal to jointly commercialize Movantik in the U.S.</li><li>Daiichi has expertise in antibody-drug conjugates (ADCs) which may have been the allure. Earlier this year, it announced that it will invest 15B yen ($136M) to raise ADC production.</li><li>AZN is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Source: Reuters</li><li><strong>Update</strong>: In a <a href=\"http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006708/170831_763_E.pdf\" target=\"_blank\">statement</a>, Daiichi says it did not receive an acquisition offer from AZN.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292883\" data-linked=\"AstraZeneca tried to buy Daiichi Sankyo last year - report\" data-tweet=\"$AZN $AZN $DSKYF - AstraZeneca tried to buy Daiichi Sankyo last year - report https://seekingalpha.com/news/3292883-astrazeneca-tried-to-buy-daiichi-sankyo-last-year-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3292883-astrazeneca-tried-to-buy-daiichi-sankyo-last-year-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292867\" data-ts=\"1504177021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DG\" target=\"_blank\">DG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292867-dollar-general-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar General beats by $0.01, beats on revenue</a></h4><ul>     <li>Dollar General (NYSE:<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a>): Q2 EPS of $1.10&nbsp;<font color='green'>beats by $0.01</font>.</li>     <li>Revenue of $5.83B (+8.2% Y/Y) <font color='green'>beats by $30M</font>.</li>     <li>Shares <font color='green'>+1.13%</font> PM.</li>     <li><a href=\"https://seekingalpha.com/pr/16928180-dollar-general-corporation-reports-second-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292867\" data-linked=\"Dollar General beats by $0.01, beats on revenue\" data-tweet=\"$DG - Dollar General beats by $0.01, beats on revenue https://seekingalpha.com/news/3292867-dollar-general-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3292867-dollar-general-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":53,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}